Exhibit 99.1

 

Babylon Again Delivers Strong Performance with Record Margins for Second Quarter 2022

 

Second quarter revenue grew 4.6x year-over-year to $265.4 million

 

U.S. value-based care members grew by 220% year-over-year

 

Adjusted EBITDA Margin of (25.9)% for the quarter, a 60% improvement year-over-year

 

Reiterating full year 2022 revenue guidance of $1.0 billion or greater and reiterating improved Adjusted EBITDA guidance of $(270.0) million

 

AUSTIN, TEXAS & LONDON, UK – August 9, 2022 – Babylon Holdings Limited (NYSE: BBLN) (“Babylon”), one of the world’s fastest-growing digital healthcare companies, today announced its financial and operating results for the second quarter ended June 30, 2022.

 

“Babylon has once again delivered very strong results that demonstrate our continued momentum.” said Ali Parsa, CEO and Founder of Babylon. “From Q2 revenue growing 4.6x to $265.4 million and U.S. value-based care members growing by 220% year-over year, to up to 7x increase in the speed of high risk member sign-up, and a 31% ER avoidance in our longest serving VBC contract, to a 7.5% improvement in medical margins in the span of three quarters, almost all our key metrics are performing well. I am truly thankful to all Babylonians for their hard work and unwavering commitment to our mission, and to our members, providers and investors for the continued trust and support."

 

Charlie Steel, Chief Financial Officer, added, “Babylon has continued its track-record of strong operational performance through the second quarter of 2022, with our Cost of Care Delivery expense reducing as a percentage of revenue from last quarter and delivering Adjusted EBITDA results ahead of consensus estimates. We continue to remain focused on profitable growth and are on track to achieve our revenue guidance of $1.0 billion or greater for the full year of 2022, alongside our improved Adjusted EBITDA guidance of $(270.0) million or less announced in July.”

 

Second Quarter Financial Results

 

Comparison of the following financial results for the three months ended June 30, 2022, compared to the three months ended June 30, 2021:

 

Total revenue was $265.4 million compared to $57.5 million, a 4.6x year-over-year increase of $207.9 million. This was primarily driven by the growth in value-based care (“VBC”) revenue, which increased by 524% year-over-year to $244.1 million in Q2 2022.

 

Loss for the period totaled $157.1 million, or a 59.2% Loss for the Period Margin, compared to Loss for the period of $64.9 million, or a 112.9% Loss for the Period Margin, in the second quarter of 2021. Loss for the Period Margin improved this quarter by 54 percentage points.

 

Claims expense increased year-over-year, from $40.4 million in Q2 2021 to $238.8 million in Q2 2022. However on a percentage basis, Medical Margin improved by 5 percentage points over the period from (3.2)% in Q2 2021 to 2.2% in Q2 2022.

 

Clinical care delivery expense increased year-over-year, from $16.0 million in Q2 2021 to $21.6 million in Q2 2022 but decreased significantly as a percentage of revenue from 27.9% to 8.2%, demonstrating operational leverage across our network.

 

Adjusted EBITDA totaled $(68.7) million, a (25.9)% Adjusted EBITDA Margin, compared to $(49.6) million Adjusted EBITDA, or (86.3)% Adjusted EBITDA Margin, in the second quarter of 2021. Adjusted EBITDA Margin improved year-over-year by 60 percentage points.

 

Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin are non-IFRS measures. An explanation of non-IFRS measures, a reconciliation of Adjusted EBITDA to the most comparable IFRS measure, Loss for the period, and the calculations of IFRS Loss for the Period Margin, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin, have been provided at the end of this press release.

 

 

Recent Highlights

 

VBC membership grew 3.2x year-on-year to a total of approximately 269,000 U.S. VBC members as of June 30, 2022. The breakout of U.S. VBC Members by health insurance program type is shown below:

 

% of Total U.S. VBC Members:  December 31, 2020   December 31, 2021   June 30, 2022 
Medicaid   88%   84%   82%
Medicare   12%   7%   12%
Commercial       9%   6%
Total U.S. VBC Members1   66,000    167,000    269,000 

 

In July 2022, we launched a new VBC contract covering 10,000 Medicare Advantage members in New Mexico, increasing the percentage of our VBC revenue from Medicare contracts to over 40% on a going forward basis.

 

Announced cost reduction actions intended to accelerate our path to profitability, which are expected to generate annual cash savings of up to $100 million. These efficiencies are being implemented during Q3 2022 with the expected financial impact predominantly from Q4 2022 onwards and subsequent periods.

 

Successful completion of the warrant exchange transaction launched in May 2022, simplifying Babylon’s capital structure, and reducing the potential dilutive impact of the public and private placement warrants.

 

During the second quarter of 2022, we recorded non-cash impairment charges of $53.2 million, primarily due the outcome of an interim impairment assessment.

 

 

1 Rounded to nearest thousand. “U.S. VBC Members” means individuals who are covered by one of our U.S. value-based care agreements with a health plan or healthcare provider. Under these agreements, we take financial responsibility for all or some of the surpluses or deficits in total actual costs under the agreement compared to our negotiated fixed per member per month, or capitation, allocation. Total U.S. VBC Members for December 31, 2020 and December 31, 2021 as per Babylon’s Annual Report on Form 20-F filed with the SEC on March 30, 2022. VBC membership figures may include some estimates for lagging data provided by health plans and may be subject to true-ups and adjustments in the future.

 

 

FY 2022 Financial Guidance

 

For the twelve months ending December 31, 2022, Babylon is reiterating its revenue guidance of $1.0 billion or greater, which represents a more than 3x increase over 2021 revenue driven predominantly by organic growth, fueled by state expansion in the U.S. with existing clients, as well as members from new clients.

 

Babylon is reiterating improved Adjusted EBITDA guidance for FY 2022 from $(295.0) million or less to $(270) million or less, implying a significant improvement in Adjusted EBITDA Margin from (184)% and (54)% in 2020 and 2021, with forecasted monthly Adjusted EBITDA of $(18) million or less by December 2022. Babylon continues to evaluate timing to reach profitability on both a cash flow and Adjusted EBITDA basis, which we are targeting as no later than 2025.

 

These statements are forward-looking and actual results may differ materially. Please refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. We are not able to reconcile projected Adjusted EBITDA loss for 2022 or December 2022, or 2022 Adjusted EBITDA Margin to its most directly comparable IFRS measure as we are not able to forecast Loss for the period on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting certain items that affect Loss for the period, including, but not limited to, changes in fair value of warrant liabilities, impairment expense, share-based compensation, foreign exchange gains or losses and gains and losses on sale of subsidiaries. Adjusted EBITDA should not be used to predict Loss for the period as the difference between the two measures is variable and may be significant.

 

Second Quarter 2022 Earnings Conference Call

 

Babylon will host a conference call to discuss second quarter 2022 results on August 9, 2022, at 5:00 p.m. Eastern Time. To participate in the Company’s live conference call and webcast, please dial (866) 682-6100 for U.S. participants, 0800 756 3429 for U.K. participants, or +1 862-298-0702 for international participants. Alternatively, you can visit the “News & Events” section of https://ir.babylonhealth.com/ to access the live webcast. On this page, you can also find a “Call me” link for instant telephone access to the event, which will be made active 15 minutes prior to the scheduled start time. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

 

Additional Notes

 

Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin are non-IFRS measures. An explanation of non-IFRS measures, a reconciliation of Adjusted EBITDA to the most comparable IFRS measure, Loss for the period, and the calculations of IFRS Loss for the Period Margin, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin, have been provided at the end of this press release.

 

Accompanying supplemental information will be posted to the Investor Relations section of Babylon’s website at https://www.babylonhealth.com.

 

About Babylon

 

Babylon is one of the world’s fastest growing digital healthcare companies whose mission is to make high-quality healthcare accessible and affordable for every person on Earth.

 

Babylon is re-engineering how people engage with their care at every step of the healthcare continuum. By flipping the model from reactive sick care to proactive healthcare through the devices people already own, it offers millions of people globally ongoing, always-on care. Babylon has already shown that in environments as diverse as the developed UK or developing Rwanda, urban New York, or rural Missouri, for people of all ages, it is possible to achieve its mission by leveraging its highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare.

 

Founded in 2013, Babylon’s technology and clinical services is supporting a global patient network across 15 countries and is capable of operating in 16 languages. In 2021 alone, Babylon helped a patient every 6 seconds, with approximately 5.2 million consultations and AI interactions. Importantly, this was achieved with a 93% user retention rate in our NHS GP at Hand service and 4 or 5 star ratings from more than 90% of our users across all of our geographies.

 

 

Babylon is also working with governments, health providers, employers and insurers across the globe to provide them with a new infrastructure that any partner can use to deliver high-quality healthcare with lower costs and better outcomes. For more information, please visit www.babylonhealth.com.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, without limitation, information concerning Babylon’s possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment and potential growth opportunities.

 

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Babylon’s management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to our future financial and operating results and that we may require additional financing; uncertainties related to our ability to continue as a going concern; the growth of our business and organization; risks associated with impairment of goodwill and other intangible assets; our failure to compete successfully; our ability to renew contracts with existing customers, and risks of contract renewals at lower fee levels, or significant reductions in members, pricing or premiums under our contracts due to factors outside our control; our dependence on our relationships with physician-owned entities; our ability to maintain and expand a network of qualified providers; our ability to increase engagement of individual members or realize the member healthcare cost savings that we expect; a significant portion of our revenue comes from a limited number of customers; the uncertainty and potential inadequacy of our claims liability estimates for medical costs and expenses; risks associated with estimating the amount and timing of revenue recognized under our licensing agreements and value-based care agreements with health plans; risks associated with our physician partners’ failure to accurately, timely and sufficiently document their services; risks associated with inaccurate or unsupportable information regarding risk adjustment scores of members in records and submissions to health plans; risks associated with reduction of reimbursement rates paid by third-party payers or federal or state healthcare programs; risks associated with regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH model; immaturity and volatility of the market for telemedicine and our unproven digital-first approach; our ability to develop and release new solutions and services; the impact of COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business; and the other risks and uncertainties identified in Babylon’s Annual Report on Form 20-F filed with the SEC on March 30, 2022, and in other documents filed or to be filed by Babylon with the SEC and available at the SEC’s website at www.sec.gov.

 

Babylon cautions that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, Babylon does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.

 

 

Table 1

Babylon Holdings Limited

Consolidated Statement of Profit and Loss and Other Comprehensive Loss

(Unaudited)

 

   For the Three Months Ended
June 30,
   For the Six Months Ended
June 30,
 
   2022   2021   2022   2021 
   $’000   $’000   $’000   $’000 
Revenue:                    
Value-based care   244,098    39,133    490,673    66,392 
Software licensing   7,375    8,281    15,131    44,245 
Clinical services   13,889    10,064    26,004    18,134 
Total revenue   265,362    57,478    531,808    128,771 
Claims expense   (238,764)   (40,384)   (486,316)   (64,301)
Clinical care delivery expense   (21,649)   (16,013)   (45,576)   (27,836)
Platform & application expenses   (13,356)   (14,943)   (30,059)   (21,377)
Research & development expenses   (18,658)   (6,811)   (28,715)   (17,201)
Sales, general & administrative expenses   (67,969)   (45,127)   (126,279)   (76,606)
Impairment expense   (53,224)       (53,224)    
Operating loss   (148,258)   (65,800)   (238,361)   (78,550)
Finance costs   (9,816)   (1,251)   (16,444)   (2,243)
Finance income   128    14    383    28 
Change in fair value of warrant liabilities   10,791        16,366     
Loss on settlement of warrants   (2,375)       (2,375)    
Exchange (loss) / gain   (7,350)   482    (7,797)   (91)
Net finance expense   (8,622)   (755)   (9,867)   (2,306)
Gain on sale of subsidiary               3,917 
Share of loss of equity-accounted investees       (821)       (1,276)
Loss before taxation   (156,880)   (67,376)   (248,228)   (78,215)
Tax (provision) / benefit   (199)   2,501    (208)   2,493 
Loss for the period   (157,079)   (64,875)   (248,436)   (75,722)
Other comprehensive loss                    
Items that may be reclassified subsequently to profit or loss:                    
Currency translation differences   1,495    1,687    (2,258)   (67)
Other comprehensive loss for the period, net of income tax   1,495    1,687    (2,258)   (67)
Total comprehensive loss for the period   (155,584)   (63,188)   (250,694)   (75,789)
Loss attributable to:                    
Equity holders of the parent   (157,079)   (64,441)   (248,436)   (74,907)
Non-controlling interest       (434)       (815)
    (157,079)   (64,875)   (248,436)   (75,722)
Total comprehensive loss attributable to:                    
Equity holders of the parent   (155,584)   (62,754)   (250,694)   (74,974)
Non-controlling interest       (434)       (815)
    (155,584)   (63,188)   (250,694)   (75,789)
Net loss per share, Basic and Diluted   (0.41)   (0.26)   (0.64)   (0.31)

 

 

Table 2

Babylon Holdings Limited

Consolidated Statement of Cash Flows

(Unaudited)

 

   For the Six Months Ended June 30, 
   2022   2021 
   $’000   $’000 
Cash flows from operating activities          
Loss for the period   (248,436)   (75,722)
Adjustments to reconcile Loss for the period to net cash used in operating activities:          
Share-based compensation   18,966    12,344 
Depreciation and amortization   21,402    13,322 
Impairment expense   53,224     
Finance costs   16,444    2,243 
Finance income   (383)   (28)
Change in fair value of warrant liabilities   (16,366)    
Loss on settlement of warrants   2,375     
Exchange loss   7,797    91 
Taxation   208    (2,493)
Gain on sale of subsidiary       (3,917)
Share of loss of equity-accounted investees       1,276 
    (144,769)   (52,884)
Working capital adjustments          
Decrease / (increase) in trade and other receivables   5,489    (12,414)
Increase / (decrease) in trade and other payables   12,335    44,372 
(Increase) / decrease in assets/liabilities held for sale       1,460 
Net cash used in operating activities   (126,945)   (19,466)
Cash flows from investing activities          
Development costs capitalized   (17,449)   (16,254)
Capital expenditures   (6,977)   (2,444)
Interest received   383    7 
Proceeds from sale of investment in subsidiary       2,213 
Payment for acquisition of subsidiaries       (13,835)
Purchase of shares in associates and joint ventures       (5,000)
Net cash used in investing activities   (24,043)   (35,313)
Cash flows from financing activities          
Proceeds from issuance of notes and warrants   100,000     
Payment of equity and debt issuance costs   (5,499)    
Interest paid   (4,644)   (1,826)
Principal payments on leases   (2,435)   (2,293)
Other financing activities, net   (1,736)   (366)
Net cash provided by (used in) financing activities   85,686    (4,485)
Net increase in cash and cash equivalents   (65,302)   (59,264)
Cash and cash equivalents at January 1,   262,581    101,757 
Effect of movements in exchange rate on cash held   (10,322)   (112)
Cash and cash equivalents at end of period   186,957    42,381 

 

 

Table 3

Babylon Holdings Limited

Consolidated Statement of Financial Position

(Unaudited)

 

   June 30, 2022   December 31, 2021 
   $’000   $’000 
ASSETS          
Non-current assets          
Right-of-use assets   17,972    7,844 
Property, plant and equipment   26,698    24,990 
Goodwill   43,041    93,678 
Other intangible assets   105,846    111,421 
Total non-current assets   193,557    237,933 
Current assets          
Right-of-use assets   5,057    3,999 
Trade and other receivables   28,333    24,119 
Prepayments and contract assets   18,417    26,000 
Cash and cash equivalents   186,957    262,581 
Total current assets   238,764    316,699 
Total assets   432,321    554,632 
EQUITY AND LIABILITIES          
EQUITY          
Ordinary share capital   16    16 
Share premium   927,183    922,897 
Share-based payment reserve   101,132    80,371 
Retained earnings   (1,086,422)   (837,986)
Foreign currency translation reserve   (2,285)   (27)
Total capital and reserves   (60,376)   165,271 
Total equity   (60,376)   165,271 
LIABILITIES          
Non-current liabilities          
Loans and borrowings   268,665    168,601 
Contract liabilities   54,781    70,396 
Lease liabilities   18,028    8,442 
Deferred grant income   7,504    7,236 
Deferred tax liability   764    1,019 
Total non-current liabilities   349,742    255,694 
Current liabilities          
Trade and other payables   30,818    22,686 
Accruals and provisions   43,283    36,856 
Claims payable   38,657    24,628 
Contract liabilities   20,552    23,786 
Warrant liability   2,881    20,128 
Lease liabilities   5,245    4,190 
Deferred grant income   1,519    1,208 
Loans and borrowings       185 
Total current liabilities   142,955    133,667 
Total liabilities   492,697    389,361 
Total liabilities and equity   432,321    554,632 

 

 

Table 4

Babylon Holdings Limited

Non-IFRS Financial Measures

(Unaudited)

 

EBITDA is defined as profit (loss) for the period, adjusted for finance costs and income, depreciation and amortization, and tax provision or benefit. Adjusted EBITDA is defined as profit (loss) for the period, adjusted for finance costs and income, depreciation and amortization, tax provision or benefit, impairment expenses, change in fair value of warrant liabilities, loss on settlement of warrants, share-based compensation, foreign exchange gain or loss, restructuring and other one-time benefit arrangements and gain or loss on sale of subsidiaries. Loss for the period is the most directly comparable IFRS measure to Adjusted EBITDA. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Total revenue for the corresponding period. Medical Loss Ratio and Medical Margin are derived from amounts presented in the Statement of Profit and Loss included in the table below.

 

We believe that EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin (collectively, the “Non-IFRS Measures”) are useful metrics for investors to understand and evaluate our operating results and ongoing profitability because they permit investors to evaluate our recurring profitability from our ongoing operating activities.

 

EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin have certain limitations, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under IFRS. We caution investors that amounts presented in accordance with our definitions of any of the Non-IFRS Measures may not be comparable to similar measures disclosed by other issuers, because some issuers calculate certain of the Non-IFRS Measures differently or not at all, limiting their usefulness as direct comparative measures.

 

 

The following table presents a reconciliation of specific IFRS measures to the Non-IFRS Measures used by management. These include EBITDA and Adjusted EBITDA from the most directly comparable IFRS measure, Loss for the period, and the calculations of IFRS Loss for the Period Margin, Adjusted EBITDA Margin, Medical Loss Ratio and Medical Margin, for the three and six months ended June 30, 2022 and 2021:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2022   2021   2022   2021 
   $’000   $’000   $’000   $’000 
Loss for the period   (157,079)   (64,875)   (248,436)   (75,722)
Adjustments to calculate EBITDA:                    
Finance costs and income   9,688    1,237    16,061    2,215 
Depreciation and amortization   11,944    7,474    21,402    13,322 
Tax provision / (benefit)   199    (2,501)   208    (2,493)
EBITDA   (135,248)   (58,665)   (210,765)   (62,678)
Adjustments to calculate Adjusted EBITDA:                    
Impairment expense   53,224        53,224     
Change in fair value of warrant liabilities   (10,791)       (16,366)    
Loss on settlement of warrants   2,375        2,375     
Share-based compensation   10,564    9,542    18,966    12,344 
Exchange loss / (gain)   7,350    (482)   7,797    91 
Restructuring and other one-time benefit arrangements   3,848        3,848     
Gain on sale of subsidiary               (3,917)
Adjusted EBITDA   (68,678)   (49,605)   (140,921)   (54,160)
                     
Total revenue   265,362    57,478    531,808    128,771 
Value-based care revenue   244,098    39,133    490,673    66,392 
Claims expense   (238,764)   (40,384)   (486,316)   (64,301)
                     
IFRS Loss for the Period Margin   (59.2)%   (112.9)%   (46.7)%   (58.8)%
Adjusted EBITDA Margin   (25.9)%   (86.3)%   (26.5)%   (42.1)%
                     
Medical Loss Ratio   97.8%   103.2%   99.1%   96.9%
Medical Margin   2.2%   (3.2)%   0.9%   3.1%

 

Contacts:

 

Media

press@babylonhealth.com

 

Investors

investors@babylonhealth.com